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Background: Emerging radiation technologies are expected to provide a positive impact
on the reduction in postoperative complications in patients receiving prosthetic breast
reconstruction. This study aimed to determine whether hypofractionated radiation therapy
(RT) with volumetric modulated arc therapy(VMAT) is superior to conventional RT in the
setting of prosthetic reconstruction.
Methods: From retrospective data collections, postoperative complications were
compared for all patients with mastectomy and staged prosthetic reconstruction
without RT, with hypofractionation using 40 Gy in 15 fractions with VMAT (Hypo-VMAT)
or conventional RT (50 Gy over 5 weeks). After harvesting subpectoral capsules from
patients with informed consents, histologic analysis including immunohistochemistry and
immunofluorescence for collagen type I, a-smooth muscle actin, CD34 and CD31
expression was performed.
Results: A total of 288 reconstructions without RT, 55 reconstructions with Hypo-VMAT,
and 29 reconstructions with conventional RT were examined. During average follow-up
period of 34.8 months, rates of overall complications were 6.3% in the no-radiation group,
18.2% in Hypo-VMAT group and 44.8% in conventional-RT group with significant
differences (no-RT vs Hypo-VMAT: p=0.006; Hypo-VMAT vs conventional-RT:
p=0.012). Levels of myofibroblasts and tissue fibrosis were lower in the Hypo-VMAT
group than in conventional-RT group (p=0.016 and p=0.040, respectively), while those of
progenitor cells and microvessel density were higher in the Hypo-VMAT group than in
conventional-RT group (p<0.001 and p<0.001, respectively).November 2020 | Volume 10 | Article 5771361
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Frontiers in Oncology | www.frontiersin.orgConclusion: We demonstrated that hypofractionated RT with VMAT served to reduce
radiation-related morbidities in prosthetic reconstruction from a clinicopathologic
perspective, compared to conventional RT. It may offer a practical strategy to mitigate
radiation-related complications in clinical settings.Keywords: prostheses and implants, mammaplasty, dose hypofractionation, radiotherapy, intensity-modulated,
postoperative complicationsINTRODUCTION
Breast cancer treatment continues to undergo paradigmatic
evolution in the field of oncologic and reconstructive surgery.
Due to insurance reimbursements in respective localities,
increased incidence of contralateral prophylactic mastectomy,
and advances in surgical technique, rates of prosthetic based
breast reconstruction are growing (1, 2). The indications for
post-mastectomy radiation therapy(PMRT) have been expanded
due to evidence of benefit local control and survival in early
breast cancer with a positive axillary node as well as advanced
and intermediate-risk breast cancer (3, 4). However, the
combination of the PMRT and prosthetic based breast
reconstruction significantly increases complication rates,
putting the treating physicians in a challenging situation (5, 6).
Previously, breast reconstruction with a prosthetic device
combined with irradiation had not been recommended due to
high reconstruction failure rate and negative impact on patient
satisfaction (5–7). Recent studies report that complications and
aesthetic results of prosthetic reconstruction in the setting of
PMRT have improved to acceptable levels compared to prior
studies (8–11). Improved outcomes may be attributable to newer
prostheses, staged prosthetic reconstruction, use of acellular
dermal matrix and advancements in radiation therapy (RT).
Furthermore, advances in radiation techniques such as prone
positioning are expected to reduce complication rate by
decreasing the maximum skin dose (12).
New advances in the use of hypofractionated radiation are
gaining wide popularity due to patient convenience and reduced
cost of care (13, 14). The oncologic rationale for hypofractionated
treatment is based on the emerging evidence that breast cancer is
more sensitive to fraction size than previously thought, implying
that conventional fractionation with small fractions has no
advantage (15). Multiple prospective randomized trials established
the role of hypofractionated RT in whole breast irradiation and
PMRT: local control was equal, and cosmetic results and
complications were similar or better with hypofractionation
compared with conventional fractionation (13, 16–18).
When considering radiation delivery, intensity-modulated
radiotherapy (IMRT) represents the next evolution of
conforming techniques. Prior, 3-dimensional conformal RT
(3D-CRT) that is currently more popular in most countries,
utilizes multiple uniform beams to spatially plan the distribution
of radiation dosage. This technique relies on forward planning,
whereby the treatment parameters (beams, shape, intensity,
angle) are decided, and resultant dose distribution are
evaluated. However, healthy tissues may not be completely2
excluded. IMRT incorporates nonuniform intensity of
radiation beams by modulating each beam’s photon fluence
(12, 19). Volumetric modulated arc therapy(VMAT) is a new
type of IMRT, which continuously optimizes the radiation
intensity as it rotates around the patient body. Computerized
inverse planning allows radiation oncologists to select the desired
dosage distribution for better dose homogeneity to the tumor,
after which computerized models optimize treatment parameters
to spare surrounding tissues (20).
In the process of adopting the newer radiation techniques,
hypofractionated RT and VMAT for PMRT at our institution, we
were able to observe a reduction in RT-related complications in
patients receiving prosthetic reconstruction. Herein, we seek to
compare clinical and histological outcomes between patients
undergoing prosthetic breast reconstruction and hypofractionated
RTwith VMAT, conventional RTwith 3D-CRT, and no irradiation.MATERIALS AND METHODS
Patient Selection
A retrospective review of all breast cancer patients undergoing
mastectomy and immediate prosthetic reconstruction between
July 2012 and April 2018 was performed. This study was only
limited to patients (N=373) treated with a consistent technique
of immediate two-staged expander/implant reconstruction using
acellular dermal matrix by two experienced plastic surgeons
(D.W.L and S.Y.S) to limit bias related to differing types of
reconstruction and surgeon experience. Five experienced
oncologic surgeons performed the mastectomies. Exclusion
criteria included patients receiving RT before mastectomy,
combined techniques such as prophylactic mastectomy,
unfinished staged reconstruction, implant plus flap and
delayed reconstructions.
A total of 373 patients were divided into two groups: one that
received PMRT, and the other, categorized as the no-RT group,
that did not. The former cohort was further stratified into
receiving either conventional fractionation (50.4 Gy in 28
fractions) with 3D-CRT or hypofractionation schedule (40.05
Gy in 15 fractions) with VMAT. These groups were referred to as
the conventional-RT or the Hypo-VMAT group, respectively.
Patients who received other combinations of RT techniques were
excluded from the study. Hypo-VMAT group was compared
with no-RT group and conventional-RT group as controls. The
study was approved by the Institutional Review Board of
Severance Hospital, Yonsei University Health System (IRB No.
4-2019-0204).November 2020 | Volume 10 | Article 577136
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Surgical techniques and reconstruction protocol were uniform
for all patients. After the mastectomy, an expander was
introduced under the pectoralis muscle and lower lateral
portion of the implant was covered with an acellular dermal
matrix sling. An expander was prefilled depending on the closing
tension of mastectomy flap. Inflation of expander began two
weeks after the first operation and recurred every two to three
weeks. Prior to radiation therapy, the expander was deflated to
reduce interference with RT (21). Immediately following
completion of RT, re-expansion was performed every two to
three weeks until the desired breast volume was reached. The
second stage of reconstruction occurred at least 3 months after
completion of RT. In all cases, expanders were removed and
shaped implants were placed.
Radiation Protocol
PMRT was performed within 6 weeks after mastectomy or
completion of the last cycle of adjuvant chemotherapy.
Administered daily from Monday to Friday, targeted tissues
included the ipsilateral chest wall, mastectomy scar and
regional nodal basins including axillary nodes, internal
mammary lymph nodes, and supraclavicular lymph nodes. RT
techniques have been described in detail previously (22). Briefly,
in the conventional-RT group, the chest wall was irradiated with
2 tangential photon beams and supraclavicular node with
anterior photon beam with 50.4 Gy in 28 fractions of 1.8 Gy
using the 3D-CRT technique. Bolus material was used in patients
who have a high risk of skin recurrence to ensure that skin was
covered adequately at the discretion of the physician. In the
Hypo-VMAT group, the prescription dose was 40.05 Gy in 15
daily fractions of 2.67 Gy. Bolus material was used in patients
who had a thin chest wall at physician’s discretion (Figure 1).Frontiers in Oncology | www.frontiersin.org 3Arc-based VMAT (Elekta Infinity Linac, Elekta, Crowley, UK)
was used in all patients with hypofractionated regimen.
Clinical Assessment
Patient information was collected from hospital electronic
medical records including demographics and RT-related
complications. Complications relevant to RT were categorized
as capsular contracture, wound dehiscence with prosthesis
exposure, peri-prosthetic infection, and cellulitis. Overall
complication rate was defined as the rate of patients with at
least one complication among those complications. Capsular
contracture was defined as modified Baker classification grade
III-IV using the modified Baker classification for reconstructed
breasts (23). Complications that occurred prior to RT were
excluded. Patient characteristics and complications were
compared between groups. In addition, conditions that
required major revisional surgery due to postoperative
complications were examined. The major revisional surgery
included implant change, explantation of the implant, and
coverage with a latissimus dorsi flap.
Histologic Analyses
Following patient consents (n=9 in each group), histologic
samples were taken from the subpectoral capsules at the
second stage breast reconstruction exchanging expander with a
permanent implant. Harvested tissue samples were fixed with
10% formaldehyde, embedded in paraffin blocks and
mounted on slides. The slides were analyzed according to
immunohistochemistry and immunofluorescence protocol.
Immunohistochemistry was performed to measure the amount
of a-smooth muscle actin (a-SMA), collagen type I (col-1) and
CD34 (progenitor cell marker), and microvessel density from the
CD31-positive vessel count as previously described.11 Semi-FIGURE 1 | Images of the 3-dimensional rendering images and computed tomography slice showing the dose distribution. (A) volumetric modulated arc therapy,
(B) 3-dimensional conformal radiotherapy.November 2020 | Volume 10 | Article 577136
Song et al. New Radiotherapy in Prosthetic Reconstructionquantitative analysis of the synthesis of a-SMA, col-1 and CD34
were executed using MetaMorph® image analysis software
(Universal Image Corporation, Buckinghamshire, UK) at high-
power field (×400). To calculate the microvessel density, the
CD31 positively stained vessels were counted at each low-power
field (×100). Results were expressed as the average value of
integrated optical density (IOD) or the average number of
vessels in 45 different digital images (5 images per one patient;
9 patients per each group) and compared between groups.
Immunofluorescence was prepared with a standard protocol
using the following primary and secondary antibodies: anti-col-1,
anti-a-SMA, anti-CD34 and anti-CD31 (Abcam, Cambridge, MA,
USA) and bovine anti-rabbit IgG-FITC and Texas Red-conjugated
bovine anti-mouse IgG (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA), respectively. Cells were viewed under a confocal
microscope system (LSM700, Olympus, Center Valley, PA, USA).
Statistical Analysis
All statistical analyses were conducted by using IBM SPSS
Statistics for Windows, version 23.0 (IBM Corp., Armonk, N.Y.,
USA). To compare the mean of continuous variables (i.e., patient
age, body mass index, breast volume, follow-up period,
quantitative values of immunohistochemistry) among the three
groups, one-way analysis of variance (ANOVA) test was used. The
Chi-squared or Fisher’s exact test was used to assess any
differences between categorical variables (i.e., histology, tumorFrontiers in Oncology | www.frontiersin.org 4stage, grade, receptor, adjuvant therapy, complication rate). Two-
tailed values of p<0.05 were considered statistically significant.RESULTS
Patients Characteristics
Among a total of 373 patients who received mastectomy and
immediate staged prosthetic reconstruction with shaped implants,
275 patients (288 reconstructions) were included in the no-RT
group, 54 patients (55 reconstructions) in the Hypo-VMAT group
and 29 patients (29 reconstructions) in the conventional-RT group.
Sixteen patients with other combinations of RT protocol were
excluded. The overall patient demographic and oncologic
characteristics are presented in Table 1. No relevant difference in
the distribution of the most characteristics between the groups was
observed with the exception of age, pathologic stage, receptors
(progesterone and triple negative) and neo-adjuvant
chemotherapy. Patients without RT had an earlier stage compared
to the other two groups, and distribution of the receptor and neo-
adjuvant therapy showed a similar pattern of differences. However,
there was no difference between Hypo-VMAT group and
conventional-RT group in all demographic and oncologic
characteristics. The average follow-up period in all patients was
34.8 ± 12.1 months.TABLE 1 | Patient demographic and oncologic characteristics.





group (n = 29)
P pno-hypo pno-cov phypo-cov
Age (year) 45.2 ± 8.9 41.7 ± 9.7 40.5 ± 10.2 0.003 0.033 0.028 >0.999
BMI (Kg/m2) 21.9 ± 3.2 22.0 ± 2.9 22.2 ± 3.3 0.891
Breast volume (ml)* 323 ± 181 324 ± 146 317 ± 155 0.984
Tumor histology 0.415
IDC 231 (80%) 43 (78%) 26 (90%)
Others 57 (20%) 12 (22%) 3 (10%)
Final stage <0.001 <0.001 <0.001 0.855
0 84 (29%) 10 (18%) 4 (14%)
I 139 (48%) 8 (15%) 4 (14%)
II 59 (20%) 21 (38%) 14 (48%)
III 6 (2%) 16 (29%) 7 (24%)
Grade 0.081
I 55 (19%) 7 (12%) 3 (10%)
II 126 (44%) 34 (62%) 14 (48%)
III 34 (12%) 8 (15%) 6 (21%)
Unknown 73 (25%) 6 (11%) 6 (21%)
Receptors
Estrogen (+) 226 (78%) 41 (75%) 20 (69%) 0.450
Progesterone (+) 178 (62%) 21 (38%) 11 (38%) 0.001 0.001 0.013 0.982
HER-2 (+) 75 (26%) 12 (21%) 6 (21%) 0.687
Triple negative 14 (5%) 7 (13%) 6 (21%) 0.002 0.057 0.005 0.357
Adjuvant therapy
Neo-adj Chemo 5 (2%) 33 (60%) 14 (48%) <0.001 <0.001 <0.001 0.303
Hormonal therapy 205 (71%) 40 (73%) 20 (69%) 0.936
Chemotherapy 99 (34%) 19 (35%) 13 (45%) 0.529
Follow-up (months) 34.8 ± 13.0 34.4 ± 8.2 35.4 ± 10.8 0.924November 2020 | Volume 10 | ArticlAll values are described as mean value ± standard deviation or number (percentage).
*Breast volume was three-dimensional surface imaging (Axis Three, AX3 Technologies, Miami, FA) (24).
RT, radiotherapy; HER-2, human epidermal growth factor receptor 2; N/A, not applicable.
pno-hypo, between no-RT group and Hypo-VMAT group; pno-cov, between no-RT group and conventional-RT group; phypo-cov, between Hypo-VMAT group and conventional-RT group.e 577136
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The rate of patients with at least one complication was lower for
the no-RT group (6.3%) compared with the Hypo-VMAT group
(18.2%) and the conventional-RT group (44.8%) (p=0.006 and
p<0.001, respectively), and there was a significant difference
between Hypo-VMAT group and conventional-RT group
(p=0.012). Each type of complication was compared between
three groups as follows: capsular contracture was present in 3.8%
of no-RT group, 10.9% of Hypo-VMAT group, and 27.6% of
conventional-RT group (p<0.001); wound dehiscence with
prothesis exposure was present in 0.3, 9.1, and 24.1%,
respectively (p<0.001); peri-prosthetic infection was present in
1.4, 3.6, and 10.3%, respectively (p=0.015); cellulitis was present
in 0.7, 3.6, and 3.4%, respectively (p=0.106). The proportions of
each complication were significantly different among the three
groups, although there was no significant difference between
Hypo-VMAT group and conventional-RT group (Table 2).
Major revisional surgery was performed with the following
frequencies: 1.0% of the no-RT group, 5.5% of Hypo-VMAT
group, and 20.7% of conventional-RT group (p<0.001).
Myofibroblast and Tissue Fibrosis
Myofibroblast plays a crucial role in capsular contracture that is
the most common complication in prosthetic breast
reconstruction. We examined the amount of a-SMA expression
using the value of IOD for immunohistochemically stained
specimens to assess the levels of myofibroblasts (11, 25). A
semi-quantitative analysis demonstrated that a-SMA expression
was significantly different between the three groups (p<0.001) and
significantly increased in the conventional-RT group (20,164 ±
21,056 IOD) compared with the no-RT group (9,504 ± 6,526 IOD;
vs conventional-RT: p=0.002) and the Hypo-VMAT group
(11,841 ± 8,615 IOD; vs conventional-RT: p=0.016). However,
there was no statistical difference between the no-RT group and
the Hypo-VMAT group (p=0.151) (Figure 2). These findings are
congruent with clinical results, suggesting hypofractionated doses
and VMAT delivery has a preventive effect on capsular
contracture over conventional-RT technology. Next, we also
measured the amount of col-1 expression in the same manner
to access the degree of tissue fibrosis, which is relevant to capsularFrontiers in Oncology | www.frontiersin.org 5contracture clinically. Tissue fibrosis is attributed to excessive
accumulation of collagen and other extracellular matrix
components (26). The amount of col-1 expression was
significantly different between the three groups (p<0.001). The
conventional-RT group (38,077 ± 18,611 IOD) had a higher
expression of col-1 than the no-RT group (20,379 ± 12,637
IOD; vs conventional-RT: p<0.001) and the Hypo-VMAT group
(31,872 ± 20,045 IOD; vs conventional-RT: p=0.040). The
difference between the no-RT group and Hypo-VMAT group
was also statistically significant (p=0.005) (Figure 2). These
findings indicate that radiation-induced fibrosis in the capsules
of the conventional-RT group stands out above that of the Hypo-
VMAT group.
CD34-Positive Progenitor Cells
CD34 is regarded as a general marker of progenitor cells (27). We
compared the level of CD34 expression between groups to
evaluate how many progenitor cells remain in each capsular
tissue. CD34 expression in the Hypo-VMAT group (28,206 ±
23,722 IOD) was significantly higher than the conventional-RT
group (14,541 ± 11,254 IOD; vs Hypo-VMAT: p=0.001), but was
significantly lower than the no-RT group (73,798 ± 56,891 IOD;
vs Hypo-VMAT: p<0.001) (Figure 3). These findings suggest
that hypofractionated doses and VMAT delivery is more likely to
preserve progenitor cells than conventional technology.
Microvessel Density
The averages of CD31-positive vessels in samples from the no-RT
group, the Hypo-VMAT group, and the conventional-RT group
were 12.91 ± 5.54, 10.44 ± 4.12, and 6.18 ± 3.76, respectively. The
difference between the Hypo-VMAT and conventional-RT group
was significant (p<0.001), suggesting that microvascular depletion
was substantial in the conventional-RT group rather than in the
Hypo-VMAT group (Figure 4).DISCUSSION
The combination of prosthetic reconstruction and PMRT is
known to be vulnerable to postoperative complications andTABLE 2 | Postoperative complications rate.





group (n = 29)
p pno-hypo pno-cov phypo-cov
Capsular contracture 11 (3.8%) 6 (10.9%) 8 (27.6%) <0.001 0.039 <0.001 0.067
Wound dehiscence 1 (0.3%) 5 (9.1%) 7 (24.1%) <0.001 <0.001 <0.001 0.098
Peri-prosthetic infection 4 (1.4%) 2 (3.6%) 3 (10.3%) 0.015 0.247 0.019 0.335
Cellulitis 2 (0.7%) 2 (3.6%) 1 (3.4%) 0.106 0.122 0.251 >0.999
Overall complications 18 (6.3%) 10 (18.2%) 13 (44.8%) <0.001 0.006 <0.001 0.012
Major revisional surgery 3 (1.0%) 3 (5.5%) 5 (20.7%) <0.001 0.055 0.001 0.058November 2020 | Volume 10 | ArticlAll values are described as number (percentage).
Overall complications rate, the rate of patients with at least one complication among radiation-related complications such as capsular contracture, wound dehiscence, peri-prosthetic
infection, and cellulitis.
RT, radiotherapy; pno-hypo, between no-RT group and Hypo-VMAT group; pno-cov, between no-RT group and conventional-RT group; phypo-cov, between Hypo-VMAT group and
conventional-RT group.e 577136
Song et al. New Radiotherapy in Prosthetic ReconstructionFIGURE 2 | Expression of collagen type I and a-SMA. Immunofluorescence of collagen type I and a-SMA and semi-quantitative analysis with immunohistochemistry
of collagen type I and a-SMA are shown. The expressions of collagen type I and a-SMA in Hypo-VMAT group are higher than those of no-radiation group, and lower
than those of conventional radiation group.FIGURE 3 | Expression of CD34. Immunofluorescence of CD34 in the three groups and semi-quantitative analysis with immunohistochemistry of CD34 are shown.
The expression of CD34 in Hypo-VMAT group is lower than that of no-radiation group, and higher than that of conventional radiation group.Frontiers in Oncology | www.frontiersin.org November 2020 | Volume 10 | Article 5771366
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reflexively select autologous over prosthetic reconstruction in
patients who are potentially PMRT candidates. However, with
multidisciplinary coordination between the oncologic surgeon,
reconstructive surgeon, and radiation oncologists, satisfactory
outcomes after prosthetic reconstruction are possible. Delayed-
immediate breast reconstruction described by Kronowitz (28) is
one such protocol. Furthermore, emerging evidence demonstrates
the possibility to overcome RT-related complication in prosthetic
reconstruction through strategies such as optimization of
reconstruction protocol (29–31), acellular dermal matrix use (11,
25–32), and prepectoral implantation (33). Reconstructive
surgeons are continually striving to reduce RT-related
complications and reconstruction failure, resulting in the
development of operative techniques and a multi-disciplinary
approach. Nevertheless, prosthetic reconstruction in the setting
of PMRT is still challenging.
Simply put, the adverse effects of radiation results from
collateral damage in radiation delivery. Minimizing injury to
healthy tissues has remained an end-goal, but has been elusive. A
recent study by Muresan et al. found that higher degree of hot
spots in breast skin was associated with RT-related
complications; they suggested prone positioning RT as a means
to decrease the maximum skin dose (12). In our previous study,
we showed the results of dosimetric analysis: conventional
fractionation regimen was a major determinant of hot spot
level within the target volume compared to hypofractionated
regimen (22). Our current data indicates that patients who
receive hypofractionated radiation with VMAT are less likely
to develop RT-related complications than those receiving
conventional RT. These results suggest that new radiation
technology using hypofractionated radiation and VMAT
reduces radiation delivery to the surrounding normal tissues
compared to conventional RT. Although the Hypo-VMAT
group was superior to the conventional-RT group, there was a
clear difference between the Hypo-VMAT group and the no-RT
group. Even with improved radiation delivery, collateral damage
is not completely eliminated. We sought to elucidate the degree
of efficacy of the new radiation technology between two controls,
no-RT group and conventional-RT group.
These clinical findings were in accordance with the histologic
results. The pathologic effects in the irradiated tissue are thoughtFrontiers in Oncology | www.frontiersin.org 7to result from the loss of stem and progenitor cells (26, 34).
Therefore, well-preserved progenitor cells imply that normal
tissues are spared from collateral damage. CD34, a progenitor
cell marker, is expressed not only by mesenchymal stromal cells
but by a multitude of other progenitor cells (35–38). The
subpectoral capsule and around tissues theoretically include
several progenitors such as mesenchymal stromal cells, muscle
satellite cells, and vascular endothelial progenitors. The CD34
positive cells in this study are postulated to be such progenitor
cells surviving after breast reconstruction with or without RT.
Progenitor cells play a pivotal role to regenerate injured tissues,
enhance wound healing, and prevent pathologic fibrosis. Given
that these regenerative mechanism defective, capsular
contracture and wound dehiscence may occur at higher rates.
Furthermore, one of the main histological changes associated
with radiation injury is vascular endothelial damage, which
causes chronic microangiopathy followed by a decrease in
tissue perfusion (34). Previous animal studies showed
hyperemia in the short term and microvasculature depletion in
the long term (39–41). Our finding in the conventional-RT
group was in line with previous results, and microvessel
density in the Hypo-VMAT group was different from that in
the conventional-RT group, suggesting the new radiation
technology exhibited less affect to the microvasculature.
As interest in hypofractionated radiation grows, studies
addressing hypofractionated PMRT have been reported recently.
A few researchers investigated the reconstructive outcomes of
hypofractionated PMRT, but they did not prove the superiority of
hypofractionated PMRT over the conventional method (15, 20, 42).
Our prior work reported that reconstructive complication rate was
lower in patients with hypofractionated RT than in patients with
conventional RT (14.3 vs 38.5%: p=0.017) (22). This current study,
an evolution of our previous work, reveals overall complications
rates were 18.2% when hypofractionated RT was combined with
VMAT, compared to 44.8% in conventional-RT group. The higher
complication rate of conventional RT in this study compared to our
previous one may be due to more extended median follow-up
period (32.5 vs 36.1 months) and inconsistency of enrolled patients,
although some are partially overlapped. This is the first study, as far
as we are aware, in which histologic analysis is performed in patients
who received hypofractionated RT for breast cancer. Nevertheless,
the results of this study have limitations of the design as aFIGURE 4 | Microvessel density from the CD31-positive vessel count. Microvessel expression by immunofluorescence of CD31 and microvessel density with
immunohistochemistry of CD34 are shown. The Microvessel density in Hypo-VMAT group is lower than that of no-radiation group, and higher than that of
conventional radiation group. White arrow, microvessel.November 2020 | Volume 10 | Article 577136
Song et al. New Radiotherapy in Prosthetic Reconstructionretrospective study in small patient series not randomly assigned to
groups. We have started a prospective multi-institutional study
(NCT 03523078). It would be expected to provide a high level of
evidence for patient-reported outcomes in patients treated with
breast reconstruction and different fractionation regimens.
Prosthetic reconstruction in the setting of PMRT is a
challenging situation which reconstructive surgeons would
inevitably encounter. Because they cannot completely avoid it,
there is a compelling need to find ways to overcome it. Our
findings provide a strategy to mitigate radiation-related
morbidities by newer radiation technologies that are not
universally popular, demonstrating that hypofractionated
breast irradiation with VMAT serves to reduce postoperative
complications as well as the collateral damage to normal tissues
with histologic evidence. Furthermore, to achieve optimal
outcomes in breast reconstruction, especially in irradiated
patients, the importance of a multidisciplinary approach
between surgeons and physicians cannot be emphasized enough.DATA AVAILABILITY STATEMENT
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